Plasma concentration of protein Z-dependent protease inhibitor and ZPI exon 3 mutations in preeclampsia.

Plasma concentration of protein Z-dependent protease inhibitor and ZPI exon 3 mutations in preeclampsia.
J Obstet Gynaecol. 2021 Jan 11;:1-4
Authors: Zhang P, Li YC, Li L, Lu Y
Abstract
Protein Z-dependent protease inhibitor (ZPI) serves as a cofactor of inhibition of FXa and FXIa by protein Z. The levels of protein Z and polymorphisms have been shown in preeclampsia (PE) patients, but the plasma levels of ZPI and ZPI gene mutations were not reported yet. The principal aim of this study was to identify the concentration of ZPI and gene polymorphism in PE. ZPI levels were determined in 113 PE patients (age: 29.9 ± 3.9 years) and in 106 controls (normal pregnancy, age: 27.0 ± 2.8 years). ZPI was measured by enzyme-linked immunosorbent assay kit, and the gene polymorphism was determined by polymerase chain reaction and sequencing. The results showed ZPI antigen was found to be significantly lower in PE patients than in controls (ZPI, 1.24 ± 0.29 mg/L vs. 1.94 ± 0.35 mg/L, p < 0.05). The exon-3 missense mutations were distributed in patients and controls and there was no convincing correlation between these mutations and PE. It was of interest to observe a close relationship between the genotypes of the exon 3 polymorphisms 181 A > G and 481 A > T in the ZPI gene. Impact statement What is already known on this subject? The occurrence of PE is closely related to dysfunction of coagulati...

Source: Journal of Obstetrics and Gynaecology - January 13, 2021 Category: OBGYN Tags: J Obstet Gynaecol Source Type: research